Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

  1. Fizazi, K.
  2. Kramer, G.
  3. Eymard, J.-C.
  4. Sternberg, C.N.
  5. de Bono, J.
  6. Castellano, D.
  7. Tombal, B.
  8. Wülfing, C.
  9. Liontos, M.
  10. Carles, J.
  11. Iacovelli, R.
  12. Melichar, B.
  13. Sverrisdóttir, Á.
  14. Theodore, C.
  15. Feyerabend, S.
  16. Helissey, C.
  17. Oudard, S.
  18. Facchini, G.
  19. Poole, E.M.
  20. Ozatilgan, A.
  21. Geffriaud-Ricouard, C.
  22. Bensfia, S.
  23. de Wit, R.
Revista:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Any de publicació: 2020

Volum: 21

Número: 11

Pàgines: 1513-1525

Tipus: Article

DOI: 10.1016/S1470-2045(20)30449-6 GOOGLE SCHOLAR lock_openAccés obert editor